Trial Profile
A Phase 1/2A, Dose Escalation, Randomized, Placebo Controlled Study of the Safety, Feasibility, and Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Chronic Tympanic Membrane Perforation
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Sep 2020
Price :
$35
*
At a glance
- Drugs Plasminogen (Primary)
- Indications Ear disorders; Tympanic membrane perforation
- Focus Adverse reactions
- Sponsors Liminal BioSciences
- 04 Sep 2020 Status changed from recruiting to discontinued.
- 30 Mar 2019 This trial has been Suspended in Sweden, according to European Clinical Trials Database.
- 28 Mar 2018 According to a ProMetic Life Sciences media release, the study is being conducted at a single center in Sweden, under the supervision of Cecilia Engmer Berglin, MD, PhD from the Department of Otorhinolaryngology at Karolinska University Hospital in Stockholm, Sweden.